Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by POXEL SA

< Previous 1 2 Next >
Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy
From POXEL SA
Via Business Wire
Poxel Announces Upcoming Participation at Investor Conferences
From Poxel SA
Via Business Wire
Poxel Announces its Financial Calendar for 2023
From Poxel SA
Via Business Wire
Poxel Announces Drawdown of the Remaining Two Tranches of its Equity-linked Financing Facility and Provides Corporate Update
From Poxel SA
Via Business Wire
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022
From Poxel SA
Via Business Wire
Poxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
From Poxel SA
Via Business Wire
Poxel Announces Upcoming Participation at the Jefferies London Healthcare Conference
From Poxel SA
Via Business Wire
Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference
From Poxel SA
Via Business Wire
Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
From Poxel SA
Via Business Wire
Availability of Poxel's 2022 Half-Year Financial Report
From Poxel SA
Via Business Wire
Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)
From Poxel SA
Via Business Wire
Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone
From Poxel SA
Via Business Wire
Poxel Reports Financial Results for First Half 2022 and Provides a Corporate Update
From Poxel SA
Via Business Wire
Poxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone
From Poxel SA
Via Business Wire
Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility
From Poxel SA
Via Business Wire
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022
From Poxel SA
Via Business Wire
Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770
From Poxel SA
Via Business Wire
Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting
From POXEL SA
Via Business Wire
Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041
From Poxel SA
Via Business Wire
Poxel Announces its Participation in Upcoming Investor and Scientific Conferences
From Poxel SA
Via Business Wire
Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2022
From Poxel SA
Via Business Wire
Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy
From Poxel SA
Via Business Wire
Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2022
From Poxel SA
Via Business Wire
Poxel Announces Availability of Its 2021 Universal Registration Document
From POXEL SA
Via Business Wire
Poxel Announces Its Participation in Upcoming Scientific Conferences
From Poxel SA
Via Business Wire
Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy
From Poxel SA
Via Business Wire
Poxel Reports Financial Results for Full Year 2021 and Provides Corporate Update
From POXEL SA
Via Business Wire
Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022
From Poxel SA
Via Business Wire
Poxel Announces PXL065 Granted FDA Fast Track Designation for X-linked Adrenoleukodystrophy
From Poxel SA
Via Business Wire
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2021 and Provides Corporate Update
From Poxel SA
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.